Researchers identify a biomarker that could predict which lung cancer patients will respond to chemotherapy.

A combination immunotherapy approach using CAR T cells could be an effective new way to treat mesothelioma.

Cell therapy has made strides in hematology and oncology and has recently shown promise in thoracic oncology. In this episode of Lung Cancer Considered host, Dr. Narjust Duma delves into this emerging therapy with guests Dr. Ben Creelan, associate professor of medicine at the University of South Florida, thoracic oncologist at Moffitt Cancer Center and Dr. Prasad Adusumilli, deputy chief and attending of the thoracic service, vice chair for translational research in the department of surgery at Memorial Sloan Kettering Cancer Center.

The routine use of epidural analgesia for patients with non-small cell lung cancer who undergo a minimally invasive lobectomy is not warranted.

Hundreds of scientists from around the world gathered at MSK last month for a symposium devoted to a promising new immunotherapy approach called CAR T cell therapy.

MSK physician-scientist Prasad Adusumilli is focused on developing more-effective immunotherapy approaches for treating tumors in the chest.

Learn why surgery is still a good option for older patients with early-stage lung cancer.

A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.

Combining checkpoint blockade with engineered T cells may lead to longer-lasting results in patients with breast cancer, lung cancer, and other solid tumors.

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.